Cargando…
Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis
Immune thrombocytopenia (ITP) may occur in isolation (primary) or in association with a predisposing condition (secondary ITP [sITP]). Eltrombopag is a well-studied treatment for primary ITP, but evidence is scarce for sITP. We evaluated real-world use of eltrombopag for sITP using electronic health...
Autores principales: | Patwardhan, Pallavi, Landsteiner, Adrienne, Lal, Lincy S., Geevarghese, Lincy, Le, Lisa, Nandal, Savita, Cuker, Adam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720735/ https://www.ncbi.nlm.nih.gov/pubmed/34505942 http://dx.doi.org/10.1007/s00277-021-04637-2 |
Ejemplares similares
-
Second‐line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records
por: Lal, Lincy S., et al.
Publicado: (2020) -
Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
por: Patwardhan, Pallavi, et al.
Publicado: (2021) -
Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023) -
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study
por: Al‐Samkari, Hanny, et al.
Publicado: (2022) -
Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)